Project description
Digital sensors to monitor mobility, disease progression
Clinicians, scientists, prominent academic centres, businesses, and the world’s largest pharmaceutical and medical industries are working together to develop a revolutionary sensor system to monitor gait in daily life. Mobility is considered the ‘sixth vital sign’ of health, with poor gait such as walking slowly being associated with greater risk of disease, cognitive decline, risk of falls, and even earlier death. The Mobilise-D project will develop digital technology, including body-worn sensors, to monitor mobility. They aim to deliver a solution for real-world digital mobility assessment and validate digital mobility outcomes to predict clinical endpoints in multiple sclerosis, hip fracture recovery, chronic obstructive pulmonary disease, and Parkinson’s disease. The results will facilitate drug development and establish a roadmap for the clinical implementation of new digital tools to identify, stratify, and monitor disability.
Objective
Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.
Fields of science
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health scienceshealth scienceshealth care services
- medical and health sciencesclinical medicinecardiology
- medical and health sciencesbasic medicineneurologyparkinson
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
NE1 7RU Newcastle Upon Tyne
United Kingdom
See on map
Participants (37)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
NE7 7DN Newcastle-Upon-Tyne
See on map
S10 2TN Sheffield
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
S10 2SB Sheffield
See on map
64239 Tel Aviv
See on map
24118 Kiel
See on map
40126 Bologna
See on map
3000 Leuven
See on map
1015 Lausanne
See on map
91054 Erlangen
See on map
4 Dublin
See on map
7491 Trondheim
See on map
70376 Stuttgart
See on map
07100 Sassari
See on map
08036 Barcelona
See on map
NE1 8ST Newcastle Upon Tyne
See on map
SW7 2AZ LONDON
See on map
20132 Milano
See on map
8006 Zurich
See on map
TW1 4JX Twickenham Middlesex
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2596HN 's-Gravenhage (Den Haag)
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
91054 Erlangen
See on map
22927 Grosshansdorf
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34000 Montpellier
See on map
Participation ended
CB4 0WD Cambridge
See on map
151 85 Sodertaelje
See on map
51373 Leverkusen
See on map
19103 Philadelphia
See on map
52078 Aachen
See on map
18 Dublin
See on map
64293 Darmstadt
See on map
4056 Basel
See on map
CT13 9NJ Sandwich
See on map
94250 GENTILLY
See on map
Participation ended
WC2B 4AE London
See on map
49131 Petach Tivka
See on map
8152 Glattpark
See on map
1831 Diegem
See on map